...
首页> 外文期刊>Journal of neurosurgery. >Stereotactic radiation treatment for recurrent nonbenign meningiomas.
【24h】

Stereotactic radiation treatment for recurrent nonbenign meningiomas.

机译:立体定向放射治疗复发性非良性脑膜瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECT: The authors analyzed the results of stereotactic radiosurgery (SRS) and stereotactic radiotherapy (SRT) for the treatment of recurrent meningiomas that were described at initial resection as showing aggressive, atypical, or malignant features (nonbenign). METHODS: Twenty-five patients who underwent SRS and/or SRT for nonbenign meningiomas between December 1992 and August 2004 were included. Thirteen of these patients underwent treatment for multiple primary or recurrent lesions. In all, 52 tumors were treated. All histological sections were reviewed and reclassified according to World Health Organization (WHO) 2000 guidelines as benign (Grade I), atypical (Grade II), or anaplastic (Grade III) meningiomas. The median follow-up period was 42 months. Seventeen (68%) of the cases were reclassified as follows: WHO Grade I (five cases), Grade II (11 cases), and Grade III (one case). Malignant progression occurred in eight cases (32%) during the follow-up period; these cases were considered as a separate group. The 3-year progression-free survival (PFS) rates for the Grades I, II, and III, and malignant progression groups were 100, 83, 0, and 11%, respectively (p < 0.001). In the Grade II group, the 3-year PFS rates for patients treated with SRS and SRT were 100 and 33%, respectively (p = 0.1). After initial treatment, 22 new tumors required treatment using SRS or SRT; 17 (77%) of them occurred inside the original resection cavity. Symptomatic edema developed in one patient (4%). CONCLUSIONS: Stereotactic radiation treatment provided effective local control of "aggressive" Grade I and Grade II meningiomas, whereas Grade III lesions were associated with poor outcome. The outcome of cases in the malignant progression group was intermediate between that of the Grade II and Grade III groups, with the lesions showing a tendency toward malignancy.
机译:目的:作者分析了立体定向放射手术(SRS)和立体定向放射疗法(SRT)治疗复发性脑膜瘤的结果,这些结果在初次切除时被描述为表现出侵袭性,非典型性或恶性特征(非良性)。方法:纳入1992年12月至2004年8月间因非良性脑膜瘤接受SRS和/或SRT治疗的25例患者。这些患者中有13名接受了多个原发或复发性病变的治疗。总共治疗了52个肿瘤。根据世界卫生组织(WHO)2000指南对所有组织学切片进行了检查并重新分类为良性(I级),非典型(II级)或间变性(III级)脑膜瘤。中位随访期为42个月。 17例(68%)的病例被重新分类如下:WHO I级(5例),II级(11例)和III级(1例)。随访期间发生恶性进展8例(32%);这些案例被视为一个单独的组。 I,II和III级以及恶性进展组的3年无进展生存率(PFS)分别为100%,83%,0%和11%(p <0.001)。在II级组中,接受SRS和SRT治疗的患者的3年PFS率分别为100%和33%(p = 0.1)。初始治疗后,需要使用SRS或SRT治疗22个新肿瘤;其中17例(77%)发生在原始切除腔内。一名患者出现症状性水肿(4%)。结论:立体定向放射治疗可以有效地控制“侵略性” I级和II级脑膜瘤,而III级病变与不良预后相关。恶性进展组病例的结局介于II级和III级组之间,病变表现出恶性倾向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号